Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man
- 8 November 1980
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 27 (18), 1673-1677
- https://doi.org/10.1016/0024-3205(80)90642-6
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Deficient metabolism of debrisoquine and sparteineClinical Pharmacology & Therapeutics, 1980
- Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquineEuropean Journal of Clinical Pharmacology, 1980
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979
- Polymorphism of carbon oxidation of drugs and clinical implications.BMJ, 1978
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- Prediction of steady-state plasma levels of nortriptyline from single oral dose kinetics: A study in twinsEuropean Journal of Clinical Pharmacology, 1973
- Urinary excretion of nortriptyline and five of its metabolites in man after single and multiple oral dosesEuropean Journal of Clinical Pharmacology, 1973
- Genetic control of nortriptyline kinetics in man: a study of relatives of propositi with high plasma concentrations.Journal of Medical Genetics, 1971
- Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapyBMJ, 1969
- Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compoundsLife Sciences, 1967